A New Clinical Model for Latinx Youth With Suicidal Behavior
This study is testing a new way to help Latinx youth (ages 12-18) who are experiencing suicidal thoughts (suicidal ideation), suicidal behaviors, or symptoms of depression. It uses a treatment called Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB), which is designed specifically for Latinx youth and their families. Some families will also receive support from a Community Health Worker (CHW). The study wants to see if adding a CHW helps youth feel better and families stay involved in treatment. Researchers will measure changes in suicidal thoughts, suicide attempts, and other suicidal events over nine months. You may be eligible if you are Latinx and have severe suicidal thoughts.
- Study design
- This interventional study plans to enroll 150 participants. It compares two approaches: SCBT-SB alone versus SCBT-SB with additional support from a Community Health Worker.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for nine months to track changes in suicidal thoughts, suicide attempts, and suicidal events.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A New Clinical Model for the Engagement of Latinx Youth With Suicidal Behavior
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Yovanska Duarte-Velez, PhD · PRINCIPAL_INVESTIGATOR · Brown University Health
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Suicidal Ideation (SI)Change from baseline to 6 months and baseline to 9 months.
Suicidal ideation measured using the Suicide Ideation Questionnaire-Junior (SIQ-JR), a self-report instrument of 15 items that measures severity of suicidal ideation as a continuous variable with established normative, reliability, and validity data for clinical and non-clinical adolescent samples. The minimum score is 0 and the maximum 90. A higher score represents increased severity and frequency of suicidal thoughts.
- Suicide Attempts (SA)Change from baseline to 6 months, 6 months to 9 months, and baseline to 9 months.
Actual and interrupted suicide attempts (yes or no) using the Columbia-Suicide Severity Rating Scale (C-SSRS).
- Suicidal Events (SE)Change from baseline to 6 months, 6 months to 9 months, and baseline to 9 months.
SE is defined as yes or no to any suicide attempt plus any ER visits due to suicidal ideation, and suicidal threats based on patient's own report and medical record, or by information gathered from the Child and Adolescent Services Assessment (CASA).
- Depressive symptoms by self-reportChange from baseline to 6 months and baseline to 9 months.
Level of depressive symptomatology using the Children Depression Inventory 2 (CDI-2). The CDI uses 27 items with a 4-point Likert type scale, the minimum score is 0 and the maximum 56. It evaluates symptoms such as depressive mood, hedonic capacity, vegetative sign, self-evaluation, and interpersonal behaviors. A higher score means higher level of depressive symptoms.
- Depressive symptoms by clinical interviewChange from baseline to 6 months and baseline to 9 months.
Depressive symptoms using the Children's Depression Rating Scale-Revised (CDRS-R). The CDRS-R is a 17-item interview assessment of depressive symptoms for school aged children and adolescents, with item rating between 1 (no difficulties) to 5 or 7 (clinically significant difficulties). The minimum raw score is 17 and the maximum 113. A higher score means higher level of depressive symptoms. It has been proposed that a score of ≥40 indicates depressive symptomatology comparable to a diagnosis of depression, whereas a score ≤28 was often used as indicative of remission within trials.